PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
Derangement of the phosphatidylinositol-3 kinase (PI3K) pathway is implicated in several subtypes of breast cancers. Mutation or upregulation of PI3K enhances cancer cells’ survival, proliferation, and ability to metastasize, making it an attractive molecular target for systemic therapy. PI3K has fo...
Guardado en:
Autores principales: | Ajay Dhakal, Luna Acharya, Ruth O’Regan, Shipra Gandhi, Carla Falkson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/de52808cef934de585708bda5de0bea6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
por: Editorial Board
Publicado: (2021) -
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
por: Yardley DA
Publicado: (2016) -
Sphingosine Kinase 1 Signaling in Breast Cancer: A Potential Target to Tackle Breast Cancer Stem Cells
por: Ling-Wei Hii, et al.
Publicado: (2021) -
Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics
por: Hui Pang, et al.
Publicado: (2021) -
Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer
por: Moradinazar M, et al.
Publicado: (2019)